Michael Bellas News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Retail sales surge as more consumers seek alternatives to carbonated, sugary drinks and more sustainable packaging

LOS ANGELES, May 11, 2021 /PRNewswire/ -- Califia Farms, a leading plant-based beverage company, was recognized as Beverage Forum’s Small Company of the Year – for companies with $1 billion in revenue or less -- by Beverage Industry Magazine and the Beverage Marketing Association. Califia Farms CEO Dave Ritterbush accepted the award and gave a keynote address at the annual event that brings together industry leaders to discuss the future of the beverage marketplace. “We’re honored by this recognition for the brand Califia has built over the last 10 years and where we are going in the ...

Episode Notes We’re offering this episode to Slate Plus listeners as a special preview of our upcoming season of shows, which launches in June. Subscribe to Slate Plus to hear the full episode now. Decoder Ring is a podcast about cracking cultural mysteries. Every episode, host Willa Paskin takes on a cultural question, object, idea, or habit and speaks with experts, historians, and obsessives to try and figure out where it comes from, what it means, and why it matters. To say that hydration is an invention is only a slight exaggeration. Back in the 1970’s and ‘80s, no one carried bottl...

BERKELEY, Calif., Feb 09, 2021 (SEND2PRESS NEWSWIRE) — Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator’s second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD). * Flightpath is led by an experienced team eager to execute deep data discovery and drive a pipeline of narrow-spectru...

BERKELEY, Calif., Feb 09, 2021 (SEND2PRESS NEWSWIRE) — Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator’s second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD). * Flightpath is led by an experienced team eager to execute deep data discovery and drive a pipeline of narrow-spectru...